Intellia presenta sólidos resultados de fase III para el tratamiento del angioedema hereditario

12 de mayo de 2026

Reportado por IA

Intellia Therapeutics presentó los resultados preliminares de su estudio de fase III HALO sobre el angioedema hereditario (AEH) durante la Conferencia Global de Atención Médica de Bank of America el 12 de mayo. Los resultados mostraron beneficios clínicos sustanciales para los pacientes con esta afección.

El director financiero Edward Dulac describió los hallazgos como muy alentadores durante la sesión. Todos los pacientes obtuvieron un beneficio clínico significativo, y el 62 por ciento permaneció libre de ataques y sin tratamiento al final del período de observación primaria de 28 semanas. Las reducciones en la tasa de ataques alcanzaron un rango superior al 80 por ciento, resultados que, según Dulac, igualan o superan informes anteriores en el campo.

High-dose fish oil linked to 43% fewer serious cardiovascular events in hemodialysis patients, trial reports

11 de marzo de 2026 Reportado por IA Imagen generada por IA Verificado por hechos

A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.

HLS Therapeutics releases Q4 2025 earnings call presentation

HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.

Syntara reports positive FDA feedback on amsulostat trial

30 de abril de 2026 Reportado por IA

Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.

Salud

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Salud

Scientists call for multi-pronged strategies against Alzheimer's

Asia

Study reveals propolis potential for metabolic disorder patients

AI identifies breast cancer drug for multiple viruses

A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.

Stem cell therapy eases frailty in older adults

27 de febrero de 2026 Reportado por IA

An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.

Gene therapy restores hearing in patients born deaf

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

12 de mayo de 2026 21:13